Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Denmark Drubmaker Novo Nordisk, BLOCKBUSTER Diabetes and Wegovy’s manufacturer Ozempt and Wegovy’s manufacturer Ozempic and Wegovy’s manufacturer, on February 5, 2025, are pictures in Novo Nordisk presented in Novo Nordisk.
Mads Claus Rasmussen | AFP | Getty pictures
Novo Nordisk On Wednesday, a better rise in the net profit, but the blockbuster wegovy lost a full annual sales increase in sales of weight loss medicines.
The net profit of the Danish pharmaceutical giant is projected by analysts in LSEG in the LSEG in the LSEG in question of the net profit of the net profit ($ 4.4 billion).
The company’s popular Wegovy obesity medication was 17.36 billion Danish cronus, 18.51 billion Danish cronus was expected by analysts by analysts with analysts expected by analysts 18.51 billion.
Common revenues in Novo Nordisk also produce diabetes and rare disease – 78.09 billion Danish croners and expected 78.18 million Danish croners.
For 2025, the company now sees sales of up to 21% to 21% in fixed exchange rates in February in February.
Novo Nordisk CEO LARS FRUGAARD Jørgensen has linked the reduced forecast to increase the rising competition from complex weight loss drugs in the United States
“We conveyed 18% sales increase in the first quarter of 2025 and continued to expand the lack of innovative GLP-1 treatment,” Jørgensen said.
“However, Lowhthan, which affects the rapid expansion of a combination in the United States, reduced our full annual outlook for planned Brand GLP-1 reputation”
U.S. echoed pharmacies were allowed to adopt the legal copies of the NOZON wegovy and diabetes under the rules of drug failure by the NOVO Dining and Medicinal Department (FDA).
In February, the FDA announced a merger to reduce copies of the drug until May 42. However, Jørgensen reiterated the company’s company would follow companies It continues to spread this kind of circumstances illegally.
The competition is heating
RESULTS, Drug Producer’s Blockbuster’s Blockbuster’s Blockbuster’s GLP-1 weight loss treatment, similar to a hormone similar to a hormone to bury the appetite
However, the company struggled to shake negative feelings after watching a number Disappointing test results The next generation is for obesity medicinal candidate Cagrisema.
The competition is heated with the weight loss drug market, Pharma firms Roche, Astrazeneca and Abbvie Currently developers potential new candidates.
Novo’s key is the US opponent Eli lilli The expectations of expectations were reported on Thursday 45% increase in the first quarterIncome for popular weight loss Zepbound came down to the lower drug prices. The US presenter has lowered the full annual earnings management due to charges related to the recent cancer treatment deal, sends shares.
